AMRX — Amneal Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapSuper Stock

Annual income statement for Amneal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,993	2,094	2,212	2,394	2,794
Cost of Revenue
Gross Profit	663	792	796	857	1,020
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,901	1,941	2,307	2,189	2,545
Operating Profit	91.3	153	-94.9	204	249
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-35.8	31.4	-248	-40.3	-55
Provision for Income Taxes
Net Income After Taxes	-41.4	20.2	-255	-48.7	-73.9
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	91.1	10.6	-130	-84	-117
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	91.1	10.6	-130	-84	-117
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.109	0.339	0.406	-0.217	-0.17